Remed Co (302550) Fair Value & Analysis
Healthcare · KR · Market cap 91.0B KRW
Fair value as of: Jun 24, 2026
Analysis
Remed Co (302550) currently trades at 2,605 KRW, while our model-based Fair Value estimate is 454.34 KRW — implying the stock looks roughly 82.6% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Remed Co.,Ltd. engages in the manufacture and supply of medical devices worldwide. The company offers transcranial magnetic stimulator, a technology for the treatment of disorders, such as stroke, autism, dementia, Parkinson's disease, developmental disorders, and tinnitus. It also offers neuro magnetic stimulation systems for helping blood circulation, treating pain, neurons, regenerating cells, and contraction and relaxation of muscles, as well as core muscle strengthening magnetic stimulation to enable building toned and shaped muscles. In addition, the company provides extracorporeal shock wave therapy; and technology to activate the sensory function of prostate and strengthen the pelvic floor muscle by stimulating them with electromagnetic pulse. The company was formerly known as CR Technology Co., Ltd. and changed its name to Remed Co., Ltd. in 2013. Remed Co., Ltd. was founded in 2003 and is headquartered in Daejeon, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Remed Co (302550) undervalued?
What is the fair value of 302550?
What is the quality score of 302550?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.